<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062763</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2009-017033-22</org_study_id>
    <secondary_id>2009-017033-22</secondary_id>
    <nct_id>NCT01062763</nct_id>
  </id_info>
  <brief_title>The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension</brief_title>
  <acronym>SDHDS</acronym>
  <official_title>South Danish Hypertension and Diabetes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ib Abildgaard Jacobsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect of spironolactone on blood pressure
      resistant to therapy in type-2 diabetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary object of the study is to estimate the effect of addition of low dose
      spironolactone to antihypertensive treatment with at least three antihypertensive drugs in
      patients with type-2 diabetes and blood pressure over 130/80 mmHg.

      Secondary aims are to estimate how many of these patients have their blood pressure
      controlled by the addition of spironolactone, to investigate whether the addition of
      spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the
      incidence of adverse effects of the aldosterone antagonist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of of Systolic Blood Pressure</measure>
    <time_frame>4 months</time_frame>
    <description>Change of systolic blood pressure from baseline to study end at four months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Diastolic Blood Pressure</measure>
    <time_frame>4 months</time_frame>
    <description>Change of diastolic blood pressure from baseline to study end at four months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>Hypertension, Resistant to Conventional Therapy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>addition of spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>spironolactone is added to previous antihypertensive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Addition of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone</intervention_name>
    <description>25 to 50 mg once daily</description>
    <arm_group_label>addition of spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>addition of placebo 1 to 2 tablets daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 75 years

          -  Type-2 diabetes

          -  Therapy resistant hypertension (by ABPM)

          -  Treatment with at least 3 antihypertensives

        Exclusion Criteria:

          -  HbA1c &gt; 10.0

          -  BP &gt; 180/110 mmHg

          -  Secondary hypertension

          -  Intolerance to spironolactone

          -  Permanent treatment with nonsteroidal antiinflammatory drugs or systemic
             glucocorticoids

          -  Total cholesterol 10 mmol/l

          -  New York Heart Association class III and IV

          -  Pregnancy or planned pregnancy

          -  Psychiatric disease

          -  Malignant disease

          -  Insufficient adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ib A Jacobsen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <reference>
    <citation>Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens. 2002 Feb;20(2):333-8.</citation>
    <PMID>11821720</PMID>
  </reference>
  <reference>
    <citation>Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov;16(11 Pt 1):925-30.</citation>
    <PMID>14573330</PMID>
  </reference>
  <reference>
    <citation>Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006 Jul;19(7):750-5.</citation>
    <PMID>16814132</PMID>
  </reference>
  <reference>
    <citation>Chapman N, Dobson J, Wilson S, Dahl√∂f B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45. Epub 2007 Feb 19.</citation>
    <PMID>17309946</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>April 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2014</results_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Ib Abildgaard Jacobsen</investigator_full_name>
    <investigator_title>Consultant physician, associate professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>spironolactone</keyword>
  <keyword>antihypertensive treatment</keyword>
  <keyword>Type-2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from outpatient clinics of endocrinology at two university hospitals and two general hospitals in the period from May 2010 to March 2012.</recruitment_details>
      <pre_assignment_details>163 patints screened. 44 screenfailures due to exclusion criteria as indicated. 119 randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>1tablet of matching placebo trated up to 2 if neccessary</description>
        </group>
        <group group_id="P2">
          <title>Addition of Spironolactone</title>
          <description>spironolactone is added to previous antihypertensive treatment
placebo : addition of placebo 1 to 2 tablets daily
spironolactone : 25 to 50 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58">119 randomized.</participants>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Addition of Spironolactone</title>
          <description>spironolactone is added to previous antihypertensive treatment
placebo : addition of placebo 1 to 2 tablets daily
spironolactone : 25 to 50 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="7.1"/>
                    <measurement group_id="B2" value="63.9" spread="6.9"/>
                    <measurement group_id="B3" value="63.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of of Systolic Blood Pressure</title>
        <description>Change of systolic blood pressure from baseline to study end at four months.</description>
        <time_frame>4 months</time_frame>
        <population>Analysis by intention to treat using LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Addition of Spironolactone</title>
            <description>spironolactone is added to previous antihypertensive treatment
spironolactone : 25 uptrated if necessary to 50 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1tablet of matching placebo uptrated to 2 if neccessary</description>
          </group>
        </group_list>
        <measure>
          <title>Change of of Systolic Blood Pressure</title>
          <description>Change of systolic blood pressure from baseline to study end at four months.</description>
          <population>Analysis by intention to treat using LOCF</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" lower_limit="-12.8" upper_limit="-6.3"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-3.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <time_frame>4 months</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Addition of Spironolactone</title>
            <description>spironolactone is added to previous antihypertensive treatment
spironolactone : 25 uptrated if necessary to 50 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1tablet of matching placebo uptrated to 2 if neccessary</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Diastolic Blood Pressure</title>
        <description>Change of diastolic blood pressure from baseline to study end at four months.</description>
        <time_frame>4 months</time_frame>
        <population>Analyzed by intention to treat and last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Addition of Spironolactone</title>
            <description>spironolactone is added to previous antihypertensive treatment
spironolactone : 25 uptrated if necessary to 50 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1tablet of matching placebo uptrated to 2 if neccessary</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Diastolic Blood Pressure</title>
          <description>Change of diastolic blood pressure from baseline to study end at four months.</description>
          <population>Analyzed by intention to treat and last observation carried forward</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-6.0" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.8" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Addition of Spironolactone</title>
          <description>spironolactone is added to previous antihypertensive treatment
spironolactone : 25 uptrated if necessary to 50 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1tablet of matching placebo uptrated to 2 if neccessary</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Serious hyperkalemia</sub_title>
                <description>Plasma potasium above 5.5 mmol/l</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ib A. Jacobsen</name_or_title>
      <organization>Dept. of Endocrinology, Odense University Hospital</organization>
      <phone>+45 27203135</phone>
      <email>ib.abildgaard@rsyd.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

